Juravinski Cancer Centre, Department of Oncology, McMaster University, Hamilton, ON, Canada.
Breast Cancer Res Treat. 2010 Jan;119(1):13-24. doi: 10.1007/s10549-009-0566-z.
The purpose of the study is to review the clinical studies relevant to the prognosis and prognostic associations of BRCA1- and BRCA2-associated breast cancers. Reports of relevant studies obtained from a MEDLINE search and references from these articles were critically reviewed. A number of methodologic limitations have been identified in the early studies. More recent studies have failed to demonstrate, for the most part, a significant overall survival difference between BRCA-associated breast cancers and sporadic breast cancers. The risk of in-breast tumor recurrence also appears to be similar in the first 5 years following a breast cancer diagnosis with apparent increase in the risk after 5 years in one study. Many in-breast tumor recurrences are now considered to be second primary breast cancers. There is a significant increase in the risk of contralateral breast cancers in BRCA mutation carriers with an estimated 10-year risk ranging from 20-40%. The prognosis of BRCA-associated breast cancers appears to be similar to that of sporadic breast cancers based on the current literature. Future data from large prospective cohort studies will be of interest.
本研究旨在回顾与 BRCA1 和 BRCA2 相关性乳腺癌的预后及其预后相关性相关的临床研究。通过 MEDLINE 检索获得相关研究报告，并对这些文章的参考文献进行了批判性评价。早期研究中已经确定了一些方法学限制。最近的研究大多未能证明 BRCA 相关性乳腺癌与散发性乳腺癌之间的总生存率存在显著差异。在乳腺癌诊断后的前 5 年内，乳房内肿瘤复发的风险似乎也相似，在一项研究中，5 年后风险明显增加。许多乳房内肿瘤复发现在被认为是第二原发乳腺癌。BRCA 突变携带者患对侧乳腺癌的风险显著增加，估计 10 年风险范围为 20%-40%。根据目前的文献，BRCA 相关性乳腺癌的预后似乎与散发性乳腺癌相似。未来来自大型前瞻性队列研究的数据将是有趣的。
